RLAYRelay Therapeutics, Inc.
Is the business good?
Margins steady. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margins have held roughly steady, a stable cost structure.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is RLAY?
Relay Therapeutics, Inc. earns −32% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 41 points below what the capital costs: growth destroys value
- Operating margin
- −2999%
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- R&D as % of revenue
- 2616%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −68% |
| FY2021 | −12040% |
| FY2022 | −21671% |
| FY2023 | −1460% |
| FY2024 | −3722% |
| FY2025 | −1972% |
Details›
- Operating margin12 months to Q2 2026
- −2999%
- Net margin12 months to Q2 2026
- −2764%
- R&D as % of revenue
- 2616%
- Revenue, trailing twelve months
- $10M
- Net income, trailing twelve months
- −$286M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −32%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.